Business Description
CStone Pharmaceuticals
ISIN : KYG2588M1006
Compare
Compare
Traded in other countries / regions
02616.Hong KongPH4.GermanyCSPHF.USA IPO Date
2019-06-14Description
CStone Pharmaceuticals is engaged in the development and commercialization of tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.43 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 0.72 | |||||
| Debt-to-EBITDA | -2.57 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -6.46 | |||||
| Beneish M-Score | -1.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -30.1 | |||||
| 3-Year EBITDA Growth Rate | 42.7 | |||||
| 3-Year EPS without NRI Growth Rate | 30.2 | |||||
| 3-Year FCF Growth Rate | 4.8 | |||||
| 3-Year Book Growth Rate | -49.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 25.66 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.9 | |||||
| 9-Day RSI | 58.57 | |||||
| 14-Day RSI | 58.35 | |||||
| 6-1 Month Momentum % | 71.43 | |||||
| 12-1 Month Momentum % | -12.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | |||||
| Quick Ratio | 1.45 | |||||
| Cash Ratio | 1.14 | |||||
| Days Inventory | 396.43 | |||||
| Days Sales Outstanding | 140.63 | |||||
| Days Payable | 748.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -2.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.75 | |||||
| Operating Margin % | -73.51 | |||||
| Net Margin % | -31.5 | |||||
| FCF Margin % | -95.35 | |||||
| ROE % | -31.09 | |||||
| ROA % | -8.99 | |||||
| ROIC % | -54.33 | |||||
| 3-Year ROIIC % | 1157.61 | |||||
| ROC (Joel Greenblatt) % | -90.96 | |||||
| ROCE % | -15.87 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.4 | |||||
| PB Ratio | 5.32 | |||||
| Price-to-Tangible-Book | 7.67 | |||||
| EV-to-EBIT | -14.9 | |||||
| EV-to-EBITDA | -14.9 | |||||
| EV-to-Revenue | 4.22 | |||||
| EV-to-FCF | -4.56 | |||||
| Price-to-Net-Current-Asset-Value | 23 | |||||
| Earnings Yield (Greenblatt) % | -6.71 | |||||
| FCF Yield % | -18.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CStone Pharmaceuticals Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 58.537 | ||
| EPS (TTM) (€) | -0.014 | ||
| Beta | 0.11 | ||
| Volatility % | 76.84 | ||
| 14-Day RSI | 58.35 | ||
| 14-Day ATR (€) | 0.014228 | ||
| 20-Day SMA (€) | 0.2124 | ||
| 12-1 Month Momentum % | -12.05 | ||
| 52-Week Range (€) | 0.092 - 0.3082 | ||
| Shares Outstanding (Mil) | 1,275.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CStone Pharmaceuticals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CStone Pharmaceuticals Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CStone Pharmaceuticals Frequently Asked Questions
What is CStone Pharmaceuticals(FRA:PH4)'s stock price today?
The current price of FRA:PH4 is €0.23. The 52 week high of FRA:PH4 is €0.31 and 52 week low is €0.09.
When is next earnings date of CStone Pharmaceuticals(FRA:PH4)?
The next earnings date of CStone Pharmaceuticals(FRA:PH4) is 2025-03-27 Est..
Does CStone Pharmaceuticals(FRA:PH4) pay dividends? If so, how much?
CStone Pharmaceuticals(FRA:PH4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers